Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

Abstract

Background: Fesoterodine is a newly approved drug for the treatment of overactive bladder syndrome.

Objective: The aim of this study was to review the preclinical and clinical data on fesoterodine.

Methods: The study involved a search of the Medline database and the proceedings volumes of urological congresses.

Results/conclusions: Fesoterodine functions as an orally active prodrug that is converted to the active metabolite 5-hydroxymethyltolterodine by non-specific esterases. 5-Hydroxymethyltolterodine is a muscarinic receptor antagonist. Fesoterodine is primarily eliminated as inactive metabolites along with significant renal excretion as the unchanged active metabolite 5-hydroxymethyltolterodine. Fesoterodine is indicated for use at doses of 4 and 8 mg once daily. In clinical studies both doses of fesoterodine were consistently superior to placebo in improving the symptoms of overactive bladder syndrome, with 8 mg/day having significantly greater effects than 4 mg/day.